A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 543 participants.
Also called NCT02546323
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 543 participants
- Sponsor
- Registry
-
NCT02546323
-
- Other papers using this trial's data
- Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02546323. Randomized; quadruple masking; primary purpose treatment. Start 2015-09-17 (actual); primary completion 2019-01-29 (actual). Results posted on 2019-12-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis
- Condition
- Atherosclerosis
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02546323- Content hash
32e7d1e0fc60bb66922923da0e7ed511af81626520a93664f9e6e36325d88fca